GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ampio Pharmaceuticals Inc (OTCPK:AMPE) » Definitions » Return-on-Tangible-Asset

AMPE (Ampio Pharmaceuticals) Return-on-Tangible-Asset : -122.79% (As of Dec. 2023)


View and export this data going back to 2003. Start your Free Trial

What is Ampio Pharmaceuticals Return-on-Tangible-Asset?

Return-on-Tangible-Asset is calculated as Net Income divided by its average total tangible assets. Total tangible assets equals to Total Assets minus Intangible Assets. Ampio Pharmaceuticals's annualized Net Income for the quarter that ended in Dec. 2023 was $-8.22 Mil. Ampio Pharmaceuticals's average total tangible assets for the quarter that ended in Dec. 2023 was $6.69 Mil. Therefore, Ampio Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 was -122.79%.

The historical rank and industry rank for Ampio Pharmaceuticals's Return-on-Tangible-Asset or its related term are showing as below:

AMPE' s Return-on-Tangible-Asset Range Over the Past 10 Years
Min: -358.98   Med: -73.59   Max: 231.63
Current: -92.12

During the past 13 years, Ampio Pharmaceuticals's highest Return-on-Tangible-Asset was 231.63%. The lowest was -358.98%. And the median was -73.59%.

AMPE's Return-on-Tangible-Asset is ranked worse than
76.25% of 1503 companies
in the Biotechnology industry
Industry Median: -39.32 vs AMPE: -92.12

Ampio Pharmaceuticals Return-on-Tangible-Asset Historical Data

The historical data trend for Ampio Pharmaceuticals's Return-on-Tangible-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ampio Pharmaceuticals Return-on-Tangible-Asset Chart

Ampio Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only -97.25 -86.20 -55.35 -62.34 -89.34

Ampio Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Return-on-Tangible-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -54.77 -130.84 -55.16 -58.54 -122.79

Competitive Comparison of Ampio Pharmaceuticals's Return-on-Tangible-Asset

For the Biotechnology subindustry, Ampio Pharmaceuticals's Return-on-Tangible-Asset, along with its competitors' market caps and Return-on-Tangible-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ampio Pharmaceuticals's Return-on-Tangible-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ampio Pharmaceuticals's Return-on-Tangible-Asset distribution charts can be found below:

* The bar in red indicates where Ampio Pharmaceuticals's Return-on-Tangible-Asset falls into.



Ampio Pharmaceuticals Return-on-Tangible-Asset Calculation

Ampio Pharmaceuticals's annualized Return-on-Tangible-Asset for the fiscal year that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-8.632/( (13.588+5.736)/ 2 )
=-8.632/9.662
=-89.34 %

Ampio Pharmaceuticals's annualized Return-on-Tangible-Asset for the quarter that ended in Dec. 2023 is calculated as:

Return-on-Tangible-Asset=Net Income/( (Total Tangible Assets+Total Tangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=Net Income/( (Total Assets - Intangible Assets+Total Assets - Intangible Assets)/ count )
(Q: Dec. 2023 )  (Q: Sep. 2023 )(Q: Dec. 2023 )
=-8.216/( (7.646+5.736)/ 2 )
=-8.216/6.691
=-122.79 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Asset, the net income of the last fiscal year and the average total tangible assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Dec. 2023) net income data.


Ampio Pharmaceuticals  (OTCPK:AMPE) Return-on-Tangible-Asset Explanation

Return-on-Tangible-Asset measures the rate of return on the average total tangible assets (total assets minus intangible assets). Tangible means physical in nature. Intangible Assets are assets that are not physical in nature, and typically "derive their value from legal or intellectual rights." Return-on-Tangible-Asset measures a firm's efficiency at generating profits from its tangible assets. It shows how well a company uses what it has to generate earnings. Return-on-Tangible-Assets can vary drastically across industries. Therefore, Return-on-Tangible-Asset should not be used to compare companies in different industries.


Be Aware

Like ROE and ROA, Return-on-Tangible-Asset is calculated with only 12 months data. Fluctuations in the company’s earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. Return-on-Tangible-Asset can be affected by events such as stock buyback or issuance, and by a company’s tax rate and its interest payment. Return-on-Tangible-Asset may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high Return-on-Tangible-Asset may indicate vulnerability in the durability of the competitive advantage.


Ampio Pharmaceuticals Return-on-Tangible-Asset Related Terms

Thank you for viewing the detailed overview of Ampio Pharmaceuticals's Return-on-Tangible-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Ampio Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
9800 Mount Pyramid Court, Suite 400, Englewood, CO, USA, 80112
Ampio Pharmaceuticals Inc is a biopharmaceutical company. It is focused on the development of a potential treatment for osteoarthritis of the knee ("OAK") as part of its OA-201 development program ("OA-201 program" or "OA-201").
Executives
J Kevin Buchi director 41 MOORES ROAD, FRAZER PA 19355
Michael A Martino director C/O AMBIT BIOSCIENCES CORPORATION, 11080 ROSELLE STREET, SAN DIEGO CA 92121
David R Stevens director 300 ELLIOTT AVENUE WEST, SUITE 500, SEATTLE WA 98119-4114
Elizabeth Varki Jobes director 640 LEE ROAD, CHESTERBROOK PA 19087
Philip H Coelho director C/O THERMOGENESIS CORP, 2711 CITRUS ROAD, RANCHO CORDOVA CA 95742
Holli Cherevka officer: Chief Operating Officer C/O AMPIO PHARMACEUTICALS, INC., 373 IVERNESS PARKWAY, ENGLEWOOD CO 80112
Dan Stokely officer: CFO 4810 EASTGATE MALL, SAN DIEGO CA 92121
Chilcott, Iii Thomas E. officer: Chief Financial Officer 373 INVERNESS PARKWAY, ENGLEWOOD CO 80122
Gregory A Gould officer: Chief Financial Officer 1111 MAIN STREET, SUITE 660, VANCOUVER WA 98660
Joshua R. Disbrow officer: Chief Operating Officer AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Michael Macaluso director C/O AMPIO PHARMACEUTICALS, INC., 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
Richard B Giles director 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111
David Bar-or director, officer: Chief Scientific Officer C/O AMPIO PHARMACEUTICALS, INC., 373 INVERNESS PARKWAY, SUITE 200, ENGLEWOOD CO 80112
Vaughan Lennox Clift officer: Chief Regulatory Affairs 807 NOBLE SPRINGS ROAD, HOUSTON TX 77062
Mark D Mcgregor officer: Chief Financial Officer 5445 DTC PARKWAY, SUITE 925, GREENWOOD VILLAGE CO 80111